Skip to main content
. 2020 Dec 3;27(1):1073274820977114. doi: 10.1177/1073274820977114

Figure 3.

Figure 3.

Immune-related risk signature validation. (A) High- and low-risk liver cancer patient OS was evaluated in the testing cohort. (B) A time-dependent ROC analysis of the immune-related risk signature in the testing cohort. (C) The OS of high- and low-risk liver cancer patients was assessed via Kaplan–Meier curve analyses in the overall cohort. (D) A time-dependent ROC analysis of the immune-related risk signature in the overall cohort.